Robert Schrepfer - ANI Pharmaceuticals Insider

ANIP -- USA Stock  

USD 70.86  0.37  0.52%

Mr. Robert W. Schrepfer is Vice President New Business Development and Contract Manufacturing of the Company. Mr. Schrepfer had served as the Companys Vice President of New Business Development and Contract Manufacturing and was promoted to Senior Vice President of New Business Development and Specialty Sales in May 2016. From 2005 to 2013, Mr. Schrepfer served as Assistant Portfolio Manager at Healthcare Value Capital, LLC, an SECregistered healthcare investment firm. Mr. Schrepfer comanaged the firms private equity portfolio and oversaw investments in healthcare services, devices and specialty pharmaceuticals. In addition, he was principal and founder of National Healthcare Analysis Group, LLC and served as Chief Financial Officer of National Healthcare Analysis Partners 1, LP, a partnership that seeks to identify and pursue healthcare fraud.
Age: 44  VP Since 2013  MBA    
Schrepfer is a Member of the Health Sector Advisory Council at Duke University where he earned his MBA in Finance and Health Sector Management.

Robert Schrepfer Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.7 % which means that it generated profit of $6.7 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 0.01 % meaning that it created $0.01 on every $100 dollars invested by stockholders.
The company currently holds 202.53 M in liabilities with Debt to Equity (D/E) ratio of 112.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals has Current Ratio of 3.55 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 173 people.ANI Pharmaceuticals (ANIP) is traded on BATS Exchange in USA. It is located in MINNESOTA U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

ANI Pharmaceuticals Leadership Team

Robert Brown, Chairman of the Board
Charlotte Arnold, CFO, Vice President
Mark Ginski, Vice President of Corticotropin Product Development
Robert Schrepfer, VP of New Bus. Devel. and Contract Manufacturing
Daniel Raynor, Director
Stephen Carey, CFO, Vice President
David Sullivan, VP of Quality Operations
Karen Quinn, Vice President - Corticotropin Regulatory Affairs
James Marken, VP of Operations
Peter Lankau, Director
Fred Holubow, Independent Director
Tracy Marshbanks, Director
Arthur Przybyl, CEO and President and Director
Thomas Penn, Director

Stock Performance Indicators

Current Sentiment - ANIP

ANI Pharmaceuticals Investor Sentiment
Most of Macroaxis users are presently bullish on ANI Pharmaceuticals. What is your sentiment towards investing in ANI Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.